Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. (FC-BALANCE)

keskiviikko 13. toukokuuta 2026 päivittänyt: Swiss Cancer Institute

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in CAR-T Therapy: a Randomized Trial

Bendamustine and the combination of fludarabine/cyclophosphamide are fully authorized chemotherapy agents in Switzerland for lymphoma treatment and currently used in routine clinical practice as lymphodepletion strategy before CAR-T immunotherapy, as supported by retrospective studies and clinical experience across multiple centers. None of the drugs described in this protocol are being used at unapproved doses, or in an investigational formulation. Both lymphodepletion regimens have a known safety profile and the risks and burdens imposed on participants do not exceed those encountered in routine CAR-T therapy management, as all procedures (including monitoring, supportive care, and follow-up assessments) align with standard clinical practice. Based on these assumptions, this protocol is designed to investigate the use of bendamustine as an alternative lymphodepletion therapy (which is a part of CAR-T immunotherapy protocol).

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Chimeric antigen receptor (CAR) T-cell immunotherapy (CAR-T) has emerged as an effective treatment for relapsed/refractory aggressive B-cell lymphomas. Three products that demonstrate clinical activities in relapse/refractory large B-Cell Lymphoma (LBCL), axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel are currently available. To ensure an optimal CAR-T cell expansion and proliferation inside the host once infused, lymphodepleting therapy is administered before CAR-T immunotherapy as it exerts its activities by generating the optimal cytokine and metabolites milieu to ensure engraftment and proliferation of CAR-T cells once infused, by removing anergic circulating lymphocytes responsible of the "cytokine sink effect", and by debulking immunosuppressive tumor masses by the time of CAR-T cell infusion. Nowadays, commercially approved CAR-T products use a combination of fludarabine (Flu) and cyclophosphamide (Cy), at different dosages, as the standard lymphodepletion regimen. After CAR-T cell infusion participants might experience several toxicities including hematological toxicities and resulting infective events, as a direct consequence of lymphodepleting chemotherapy infusion.

Furthermore, the participants can experience CAR-T specific toxicities such as cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS), which are the consequence of the CAR-T cell to tumor engagement activity. In fact, these toxicities are responsible for more than 60% of non-relapse mortalities after CAR-T cells and their treatment increase the hospitalization stay and overall costs of CAR-T cell immunotherapy.

Therefore, there is a great need to improve the current CAR-T cell immunotherapy treatment to reduce the risk of toxicity. A growing number of retrospective studies demonstrated that bendamustine lymphodepletion is an alternative lymphodepletion regimen. In all these studies, bendamustine lymphodepletion showed comparable response rate but drastically reduced toxicities, in terms of CRS, neurotoxicity, hematological toxicity and, in particular, infections. As a result, its use is steadily increasing across Swiss centers. There are no published and other randomized trials, currently ongoing, investigating this particular question. For these reasons, bendamustine should be tested against the current SoC lymphodepleting chemotherapy.

This trial aims to prospectively compare the safety and efficacy of bendamustine versus standard Flu/Cy lymphodepletion before CART cell therapy in participants with relapsed/refractory large B-cell lymphoma (LBCL).

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

92

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

  • Sveitsi
      • Aarau, Sveitsi, 5001
        • Kantonsspital Aarau
        • Ottaa yhteyttä:
        • Päätutkija:
          • Martina Dickenmann, MD
      • Basel, Sveitsi, 4056
        • Universitätsspital Basel
        • Ottaa yhteyttä:
        • Päätutkija:
          • Andreas Holbro, MD
      • Bellinzona, Sveitsi, 6500
        • Ente Ospedaliero Cantonale (EOC)-Istituto Oncologico della Svizzera Italiana (IOSI)
        • Ottaa yhteyttä:
        • Päätutkija:
          • Georg Stüssi, Prof
      • Bern, Sveitsi, 3010
        • Inselspital Bern - Universitätsklinik für Medizinische Onkologie
        • Ottaa yhteyttä:
        • Päätutkija:
          • Marc Wehrli, MD
      • Chur, Sveitsi, 7000
        • Kantonsspital Graubunden
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ulrich Mey, MD
      • Geneva, Sveitsi, 1211
        • Les hôpitaux universitaires de Genève
        • Ottaa yhteyttä:
        • Päätutkija:
          • Federico Simonetta, MD
      • Lucerne, Sveitsi, 6004
        • Luzerner Kantonsspital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ramona Merki, MD
      • Sankt Gallen, Sveitsi, 9007
        • HOCH Health Ostschweiz - Kantonsspital St. Gallen
        • Ottaa yhteyttä:
        • Päätutkija:
          • Martin Fehr, MD
      • Zurich, Sveitsi, 8032
        • Klinik für Hämatologie und Onkologie Hirslanden Zürich
        • Ottaa yhteyttä:
        • Päätutkija:
          • Christoph Renner, Prof

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  • Diagnosis of large B-cell lymphoma (LBCL) with at least one line of previous treatment and indication for commercial CAR-T cell therapy as determined by the treating physician. This includes: Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) and all specific DLBCL subtypes, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed follicular lymphoma, and other transformed indolent B-cell lymphomas (including transformed marginal zone lymphoma and Richter's transformation). Patients with primary or secondary central nervous system (CNS) involvement are eligible.
  • Planned treatment with commercially available CAR-T cell product
  • Age ≥18 years
  • Ability to provide written informed consent

Exclusion Criteria:

  • Administration of any other experimental drug within 5 half-lives or ≤ 4 weeks prior to lymphodepletion therapy starts.
  • Bendamustine 3 months before leukapheresis. After leukapheresis, bendamustine use is allowed as bridging therapy according to physician decision.
  • Previous administration of anti-CD19 CAR-T products within the last 12 months from lymphodepletion therapy start.
  • Known history of hypersensitivity to the active substance or any of the excipients found in the composition of bendamustine, fludarabine, or cyclophosphamide.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Arm A: Experimental Arm
Bendamustine
Lääke: bendamustine hydrochloride
  • Dose: 90 mg/m² body surface area
  • Route: Intravenous infusion
  • Administration: Infused over 30-60 minutes in 500 mL normal saline or 5% dextrose
  • Pre-medication: Standard institutional protocols for bendamustine administration (typically antiemetics)
Active Comparator: Arm B: Control Arm
Fludarabine/Cyclophosphamide
Lääke: Cyclophosphamide
  • Administration: Intravenous infusion per institutional protocols and product guidelines.
  • Dose: according to the specification described in the prescription information sheet of the CAR-T product used.
Lääke: Fludarabine
  • Administration: Intravenous infusion per institutional protocols and product guidelines.
  • Dose: according to the specification described in the prescription information sheet of the CAR-T product used.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of the following side effect occurring within 4 weeks (28 days) from the CAR-T infusion: Occurrence of grade ≥3 cytokine release syndrome (CRS)
Aikaikkuna: From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion

Primary Outcome measure consists of 3 side effects: Incidence of at least one of the following side effects occurring within 4 weeks (28 days) from the CAR-T infusion: • Occurrence of grade ≥3 cytokine release syndrome (CRS) • Febrile neutropenia • Grade ≥3 Immune effector Cell-Associated Neurotoxicit.

All infections, including those that result in febrile neutropenia, and the CRS and ICANS will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Febrile neutropenia is defined as absolute neutrophil count <1000/mm³ with fever ≥38.3°C (single measurement) or ≥38.0°C sustained for >1 hour.

Participants who remain free of any of the above listed symptoms at least 28 days from the CAR-T cell infusion AND did not stop the trial treatment will be counted as a success for this endpoint, otherwise they will be counted as a failure for the primary endpoint.
From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion
Incidence of the following side effect occurring within 4 weeks (28 days) from the CAR-T infusion: Febrile neutropenia
Aikaikkuna: From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion

Primary Outcome measure consists of 3 side effects: Incidence of at least one of the following side effects occurring within 4 weeks (28 days) from the CAR-T infusion: • Occurrence of grade ≥3 cytokine release syndrome (CRS) • Febrile neutropenia • Grade ≥3 Immune effector Cell-Associated Neurotoxicit.

All infections, including those that result in febrile neutropenia, and the CRS and ICANS will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Febrile neutropenia is defined as absolute neutrophil count <1000/mm³ with fever ≥38.3°C (single measurement) or ≥38.0°C sustained for >1 hour.

Participants who remain free of any of the above listed symptoms at least 28 days from the CAR-T cell infusion AND did not stop the trial treatment will be counted as a success for this endpoint, otherwise they will be counted as a failure for the primary endpoint.
From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion
Incidence of the following side effect occurring within 4 weeks (28 days) from the CAR-T infusion: Grade ≥3 Immune effector Cell-Associated Neurotoxicit
Aikaikkuna: From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion

All infections, including those that result in febrile neutropenia, and the CRS and ICANS will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Febrile neutropenia is defined as absolute neutrophil count <1000/mm³ with fever ≥38.3°C (single measurement) or ≥38.0°C sustained for >1 hour.

Participants who remain free of any of the above listed symptoms at least 28 days from the CAR-T cell infusion AND did not stop the trial treatment will be counted as a success for this endpoint, otherwise they will be counted as a failure for the primary endpoint.
From the start of lymphodepletion therapy until 4 weeks (day 28) after the CAR-T cell Infusion

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Best lymphoma response at 3 months post-CAR-T infusion
Aikaikkuna: From the CAR-T infusion until week 15 (inclusive) post-CAR-T infusion
Best lymphoma response at 3 months is defined as the best response assessment in the following descending order: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) or not evaluable (NE), measured as indicated on local guidelines (e.g., Lugano 2014 classification) based on PET/CT imaging. Any assessment up to week 15 (inclusive) will be considered for determining the best response.
From the CAR-T infusion until week 15 (inclusive) post-CAR-T infusion
Progression-free survival (PFS)
Aikaikkuna: from CAR-T infusion to lymphoma progression or death, up to 3.25 years after CAR-T infusion of the first patient]
PFS is defined as time from CAR-T infusion to lymphoma progression or death from any cause. Participants not experiencing an event, including participants receiving a subsequent anti-lymphoma therapy without documented disease progression or relapse, will be censored at the last time they were known to be without progression (i.e. last date of tumor assessment without progression) and before the start of a new anti-lymphoma treatment, if any.
from CAR-T infusion to lymphoma progression or death, up to 3.25 years after CAR-T infusion of the first patient]
Overall survival (OS)
Aikaikkuna: From CAR-T infusion to death, up to 3.25 years after CAR-T infusion of the first patient
Time from CAR-T infusion to death from any cause. Participants not experiencing an event will be censored at the last date they were known to be alive.
From CAR-T infusion to death, up to 3.25 years after CAR-T infusion of the first patient

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Swiss Cancer Institute

Tutkijat

  • Opintojen puheenjohtaja: Benjamin Kasenda, PD Dr. med. Dr. phil., University Hospital Basel (USB)
  • Opintojohtaja: Guido Ghilardi, Ente Ospedaliero cantonale (EOC)

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. syyskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. maaliskuuta 2029

Opintojen valmistuminen (Arvioitu)

Perjantai 1. maaliskuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 4. toukokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 13. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 18. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 18. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 13. toukokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • SCI-003_FC-BALANCE
  • 2026-525792-36-00 (Ctis)
  • U1111-1335-8513 (Muu tunniste: ICTRP)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa